Literature DB >> 33390127

Insight γ-Secretase: Structure, Function and Role in Alzheimer's Disease.

Suvadeep Mal1, Udita Malik2, Dilipkumar Pal3, Abhishek Mishra4.   

Abstract

Neurodegenerative disorders are the state of body results in progressive degeneration leading to death of nerve cells. In this state, a patient gets affected day by day with mental weakness, dementia and ataxia. Alzheimer's disease (AD) is the most common irreversible neurodegenerative brain disorder mainly affecting people over the age of 65 years. Many researches suggest a fact that the main culprit for AD is the aggregated form of a (39-43) amino acid peptide called amyloid beta. Amyloid beta (Aβ) is generated by the action of beta secretase and gamma secretase on larger glycoprotein. Gamma (γ) secretase is an intra-membrane protease complex which cleaves the single-pass transmembrane protein, cleavage of amyloid precursor protein and Notch. γ-secretase complex contains presenilin, presenilin enhancer-2, anterior pharynx defective-1 and nicastrin. Any mutation in presenilin-1 or the cleavage of amyloid precursor protein by γ-secretase directly or indirectly associated with AD. So, prevention of this enzyme is one of the solutions for AD. In this article, we discuss about γ-secretase complex and its inhibitors that can contribute to the prevention of AD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid beta; Neurodegenerative disorder; Notch; amyloid precursor protein.; amyloid precursor protein.Neurodegenerative disorder; anterior pharynx defective-1; nicastrin; presenilin; γ-secretase

Year:  2020        PMID: 33390127     DOI: 10.2174/1389450121999201230203709

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  1 in total

1.  PSEN1 is associated with colon cancer development via potential influences on PD-L1 nuclear translocation and tumor-immune interactions.

Authors:  Wangzhi Wei; Yu Zhang
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.